Head-to-head · computed 2026-08-11
MEDVi vs PlexusDx
MEDVi: MEDVi advertises a $179 semaglutide start that tiers to $299 at maintenance; tirzepatide is $399 flat. PlexusDx: PlexusDx sells flat-rate compounded protocols with no membership: $149/month semaglutide injection (flat from 0.25 to 2.0 mg weekly), $249/month tirzepatide injection (flat from 2.5 to 15 mg), a $129/month microdose protocol, and an optional genetic test the company positions as personalization.
Tirzepatide
| MEDVi | PlexusDx | |
|---|---|---|
| All-in maintenance | $399/mo | $249/mo |
| Best plan rate | $399/mo | $249/mo |
| 12-month total | $4,788 | $2,988 |
| Status | Provider-stated · 2026-08-05 | Provider-stated · 2026-08-11 |
The arithmetic
On the figures our desk holds, PlexusDx's $249 a month undercuts MEDVi's $399 by $150 a month at the 10 mg/wk maintenance basis — $1,800 across a year. PlexusDx's figure is provider-stated (captured 2026-08-11) and MEDVi's is provider-stated (captured 2026-08-05); a status below 'verified' means our independent checkout capture is still pending, so treat the gap as the best current evidence rather than settled fact.
MEDVi's tirzepatide ladder runs $399 a month billed monthly. PlexusDx's runs $249 a month billed monthly. On the twelve-month basis PlexusDx's $2,988 beats MEDVi's $4,788 by $1,800 — with the winner's figure resting on twelve months at the month-to-month rate with no commitment, a structural difference that matters if you might stop early.
Semaglutide
| MEDVi | PlexusDx | |
|---|---|---|
| All-in maintenance | $299/mo | $149/mo |
| Best plan rate | $299/mo | $149/mo |
| 12-month total | $3,588 | $1,788 |
| Status | Provider-stated · 2026-08-05 | Provider-stated · 2026-08-11 |
The arithmetic
On the figures our desk holds, PlexusDx's $149 a month undercuts MEDVi's $299 by $150 a month at the 2.4 mg/wk maintenance basis — $1,800 across a year. PlexusDx's figure is provider-stated (captured 2026-08-11) and MEDVi's is provider-stated (captured 2026-08-05); a status below 'verified' means our independent checkout capture is still pending, so treat the gap as the best current evidence rather than settled fact.
MEDVi's semaglutide ladder runs $299 a month billed monthly. PlexusDx's runs $149 a month billed monthly. On the twelve-month basis PlexusDx's $1,788 beats MEDVi's $3,588 by $1,800 — with the winner's figure resting on twelve months at the month-to-month rate with no commitment, a structural difference that matters if you might stop early.
Where the structures genuinely differ
On verifiability, MEDVi names its dispensing pharmacy — which means the fifteen-minute license-and-records check is possible — while PlexusDx's pharmacy is not disclosed on record, the single structural fact this desk weighs heaviest after the FDA's 2026 letters cited exactly that practice.
Structure, side by side
MEDVi
- MembershipNone
- Dose policyTiered on semaglutide; tirzepatide flat
- CommitmentMonth-to-month
- CancellationCancel before renewal
- PharmacyPartner pharmacies
PlexusDx
- MembershipNone
- Dose policyDose-flat per published protocol pricing (semaglutide flat across five dose levels; tirzepatide flat across six)
- CommitmentMonth-to-month
- CancellationPer published terms; confirm at checkout
- PharmacyLicensed 503A compounders (per company; names undisclosed on captured materials)
What our desk is watching on each
MEDVi: Start-vs-maintenance spread on semaglutide; compare on maintenance.
PlexusDx: Provider-stated throughout: every figure here comes from PlexusDx's own published materials, which the company distributes inside competitor 'reviews' on its blog — a marketing format worth noting even when the numbers are consistent. The optional 'Precision Peptide Genetic Test' is an upsell whose clinical utility for dose selection is not established by the class's trial record; the microdose protocol is sub-maintenance by design and is not ranked at the maintenance basis. Pharmacy names undisclosed on captured materials — the verification workflow stalls at step one until answered. Independent checkout capture pending.
Questions people ask
Is MEDVi or PlexusDx cheaper in 2026?
The tirzepatide and semaglutide verdict blocks above give the computed answer at the maintenance basis, with the verification status of each figure; the short version is that whichever program's all-in monthly number is lower on this page is cheaper on the evidence we hold today, and both rows carry capture dates so you can judge freshness.
What does MEDVi vs PlexusDx miss that checkout will show?
Taxes, state availability, current promotions, and any dose surcharge introduced after our capture date. Screenshot the order summary before paying — that capture, not any comparison page, is your contract.
Why do you compare at the maintenance dose instead of the starting dose?
Because starter pricing lasts one or two months and maintenance pricing lasts the rest of the year; comparing starts against maintenances is the single most common way GLP-1 comparisons mislead.
What do MEDVi and PlexusDx cost over a full year of tirzepatide?
On the plans our database holds, a year of tirzepatide runs $4,788 at MEDVi and $2,988 at PlexusDx — computed from each program's best published twelve-month route, with promotional figures labeled in the sections above and every number carrying its capture date.
Both records live in the normalized database; re-run the math yourself from the downloads. Full record pages: MEDVi · PlexusDx. Official sites: MEDVi ↗ · PlexusDx ↗. Nothing here is medical advice.